Valneva Investors Meetings to be Held in January 2024

ValnevaIn a press release on 01.04.2024, the specialty vaccine company announced that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings January 8 – 10, 2024 during the 42nd Annual J.P. Morgan Healthcare Conference, in San Francisco. A virtual meeting will also be held at the Oddo BHF Forum on January 15, 2024.

Thomas Lingelbach and Peter Bühlerwill will discuss Valneva’s advanced vaccine development pipeline which includes Lyme disease vaccine candidate VLA15. This Vaccine candidate is in Phase 3 clinical trials with full enrollment, and Valneva is partnered with Pfizer on this candidate.

For More Information: 

Read Press Release

Read more LDA Articles on Lyme Vaccine